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BACKGROUND
• Systemic sclerosis (SSc) is a chronic autoimmune disease characterized by fibrosis,
inflammation, autoantibody formation, and vascular abnormalities.
• There are approximately 100,000 SSc patients in the US. The incidence and prevalence rates
are much higher in females than in males.
• There are currently no validated diagnostic markers, disease altering FDA-approved
treatments or cures for this disease.
• Mechanism of disease pathogenesis is poorly understood.

MATERIALS & METHODS
•
•
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•

RESULTS CONTINUED

Healthy human peripheral blood derived monocytes were isolated by cold aggregation. Monocyte purity was > 90%.
Cells were differentiated in healthy or control plasma and treated with 15ng/ml of MCSF and 300nM CDDO-Me or vehicle
control as indicated.
Total RNA was extracted using miRNAeasy Mini Kit. cDNA was synthesized with random hexamers and analyzed by qRT-PCR.
Flow cytometry was performed using an 8-color MACSQuant 10 with three laser sources (405 nm, 488 nm, 635 nm) and
FlowLogic 501.2A software.

Figure 5: Multicolor flow cytometry was used to analyze effect of CDDO-Me on surface
expression of CD163 and CD206. Healthy and SSc macrophages were treated with DMSO or
300nM CDDO-Me for 24 hours before staining with antibodies. n=3 for this experiment.

Figure 1: Model of SSc pathogenesis. Genetic and environmental factors converge to cause the
onset of SSc. There are four hallmarks of the disease that include vascular abnormalities,
fibrosis, oxidative stress, and aberrant immune function.
• Macrophages are innate immune cells that play important roles in phagocytosis, antigen
presentation, and cytokine and chemokine production.
• Macrophage activation is plastic and is influenced by the local tissue micro-environment,
including cytokines, chemokines, growth factors, and hormones.
• Genes associated with monocyte and macrophage recruitment and differentiation are
overexpressed in SSc patients.
• Expression of TGF-β, CCL2, and IL-6, which are known to induce fibrosis, inflammation and
oxidative stress, is elevated in SSc macrophages.

CDDO-Me decreases % CD206+ healthy and SSc macrophages

RESULTS
CDDO-Me attenuates CCL2 levels in both healthy and systemic sclerosis macrophages

Figure 3: Control and SSc macrophages were
treated with DMSO or 300nM CDDO-Me for 24
hours. Total RNA was extracted, reverse
transcribed into cDNA and target genes were
amplified using qRT-PCR. Values were
normalized using b-actin. n=3 for each
experiment.

CONCLUSIONS
• CDDO-Me inhibits expression of CCL2 in both healthy and SSc macrophages.
• CDDO-Me induces Nrf2 activation in SSc macrophages, increasing expression of KEAP1
and HO-1
• CDDO-Me treatment decreases the number of healthy and SSc macrophages that express
CD206. CDDO-Me also decreases the percent of CD163-expressing healthy control
macrophages, but does not mediate changes in SSc cells.

MODEL
CDDO-Me attenuates expression of pro-fibrotic CCL2 and induces Nrf2 activation in
SSc macrophages, suggesting it may be useful as a therapeutic for SSc patients.

Figure 2: SSc macrophages produce elevated levels of pro-fibrotic mediators compared
with control cells. Macrophages from healthy controls or SSc patients were differentiated in
autologous plasma and stimulated or not with 10 ng/ml lipopolysaccharide (LPS) for 24
hours. mRNA was analyzed by qRT-PCR. n=7-8 SSc patients and 7 healthy controls; p<0.05

CDDO-Me activates the NRF2 signaling pathway

• CDDO-Me is an orally-bioavailable semi-synthetic triterpenoid with anti-inflammatory and
anti-carcinogenic properties.
• CDDO-Me is undergoing Phase III clinical trial testing for the treatment of pulmonary arterial
hypertension, which is the leading cause of death in SSc patients.

HYPOTHESIS
CDDO-Me inhibits inflammatory and fibrotic mediator production in both healthy and SSc
macrophages, resulting in decreased collagen production and inflammation.

Figure 4: Control and SSc macrophages were
treated with DMSO or 300nM CDDO-Me for 24
hours. Total RNA was extracted and reverse
transcribed into cDNA. Message for target genes
was amplified using qRT-PCR and normalized
using b-actin. n=3 for each experiment.
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